Dr Quah has over 10 years of experience in the field of oncolytic immunotherapy. Most recently he was a senior researcher in early discovery at Viralytics, where he was a key member of the team managing the company’s lead clinical candidate operations, including dose response, drug efficacy, and safety modelling in pre-clinical models.

Dr Quah holds a Doctorate in microbiology and immunology from the University of Newcastle (Australia), where he investigated the emerging role of oncolytic viruses in enhancing tumour immunotherapies. He is particularly interested in identifying predictive molecular tumour signatures that would aid in selecting the best available treatment for patients. Currently he holds a conjoint research fellow position with the University of Newcastle.